Philip McGuire
University of Oxford · King's College London
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Philip McGuire as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:23 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT07434973 · Stratification and Treatment in Early Psychosis Study - PROMOTEUniversity of Oxford · not yet recruiting · Clinical High Risk for Psychosis (CHR), Clinical High Risk for Psychosis, Clinical High Risk for Developing Psychosis · principal investigator
- Ph3NCT06778564 · Stratification and Treatment in Early Psychosis Study - ENHANCEUniversity of Oxford · recruiting · Psychosis, First Episode Psychosis, Psychotic Disorders · principal investigator
- N/ANCT02212041 · Electronic Cigarettes in Smokers With Mental IllnessKing's College London · completed · Schizophrenia, Schizophreniform Disorder, Bipolar Disorder · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:23 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:23 UTC. The ranking covers the 200 most relevant of 83 PubMed records, and a shared surname and initials can bring in a namesake. All 83 on PubMed
- Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology.Neuropsychopharmacology · 2010554 citationsRCR 18.3
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.Am J Psychiatry · 2018441 citationsRCR 23.1
- Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report.J Psychopharmacol · 2011389 citationsRCR 13.7
- Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.Arch Gen Psychiatry · 2009371 citationsRCR 12.2
- Cortical patterning of abnormal morphometric similarity in psychosis is associated with brain expression of schizophrenia-related genes.Proc Natl Acad Sci U S A · 2019348 citationsRCR 15.4
- 277 citationsRCR 7.4
- Effects of cannabidiol (CBD) on regional cerebral blood flow.Neuropsychopharmacology · 2004226 citationsRCR 6.0
- Different effects of typical and atypical antipsychotics on grey matter in first episode psychosis: the AESOP study.Neuropsychopharmacology · 2005213 citationsRCR 5.9
- Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.Arch Gen Psychiatry · 2009205 citationsRCR 6.5
- Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers.Curr Pharm Des · 2012204 citationsRCR 7.8